# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-017883
Filing Date
2024-02-21
Accepted
2024-02-21 16:01:54
Documents
136
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | alks-20231231.htm iXBRL | 10-K | 4468097
2 | EX-2.1 | alks-ex2_1.htm | EX-2.1 | 1291936
3 | EX-3.1 | alks-ex3_1.htm | EX-3.1 | 483921
4 | EX-4.1 | alks-ex4_1.htm | EX-4.1 | 99467
5 | EX-10.5 | alks-ex10_5.htm | EX-10.5 | 329347
6 | EX-10.16 | alks-ex10_16.htm | EX-10.16 | 818282
7 | EX-10.13A | alks-ex10_13a.htm | EX-10.13A | 33200
8 | EX-10.25M | alks-ex10_25m.htm | EX-10.25M | 38020
9 | EX-10.25N | alks-ex10_25n.htm | EX-10.25N | 33918
10 | EX-10.5A | alks-ex10_5a.htm | EX-10.5A | 154569
11 | EX-21.1 | alks-ex21_1.htm | EX-21.1 | 14653
12 | EX-23.1 | alks-ex23_1.htm | EX-23.1 | 3168
13 | EX-31.1 | alks-ex31_1.htm | EX-31.1 | 16242
14 | EX-31.2 | alks-ex31_2.htm | EX-31.2 | 16248
15 | EX-32.1 | alks-ex32_1.htm | EX-32.1 | 19102
16 | EX-97 | alks-ex97.htm | EX-97 | 46451
17 | GRAPHIC | img76622712_0.jpg | GRAPHIC | 90492
18 | GRAPHIC | img76622712_1.jpg | GRAPHIC | 134869
19 | GRAPHIC | img76622712_2.jpg | GRAPHIC | 43283
20 | GRAPHIC | img76622712_3.jpg | GRAPHIC | 21082
21 | GRAPHIC | img76622712_4.jpg | GRAPHIC | 98880
| Complete submission text file | 0000950170-24-017883.txt |  | 22967932

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
22 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | alks-20231231.xsd | EX-101.SCH | 2383532
138 | EXTRACTED XBRL INSTANCE DOCUMENT | alks-20231231_htm.xml | XML | 3782845

Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-35299 | Film No.: 24659291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)